EQT AB (publ) EQT.ST
Composite 58/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 10/100 — a strong mark against it.
Growth ranks 87/100 — a strong point in its favour. Balance-sheet strength ranks 75/100 — a moderate point in its favour. Quality ranks 72/100 — a moderate point in its favour.
Valuation ranks 10/100 — a strong mark against it.
What the company does EQT AB (publ) is a global private equity and venture capital firm investing across private capital, real assets, green funds, and fintech. It targets seed through late-stage ventures and buyouts in sectors including TMT, healthcare, industrials, and consumer goods, primarily in Europe and North America.
Key financials EQT reports ROE 13.9%, ROA 7.4%, and ROCE 20.7%, with gross/operating/net margins of 69.1%/47.8%/35.2%. Revenue and EPS grew 26.5% and 93.2%, respectively. Leverage is low (Debt/Equity 0.34), and liquidity is strong (Current ratio 6.39).
Stock health Momentum shows 3m +5.14%, 6m -7.32%, and RSI(14) at 67.10. The stock is -15.26% below its 52-week high. Sideravia scores highlight strong quality (72.8) but weak valuation (24.4).
Price vs fair value The stock trades at a PREMIUM of 47.40% versus our fair-value estimate of 169.48 and at a discount of 16.01% to the analyst 12-month target of 373.45. - Record PE fundraises in Asia may support EQT’s capital deployment (The Wall Street Journal) - Revolut’s partnership with Apollo and Ares underscores demand for private market exposure (Bloomberg) - EQT’s A$2.6bn perpetual bid signals confidence in perpetual capital structures (Private Banker International) - Analysts remain bullish with 11.0 price targets averaging 373.45 (analyst count 11.0)
Looking forward Forward P/E of 28.49 and PEG of 1.76 suggest valuation is rich but growth remains robust. Margins and ROCE stability will be key to justifying current premiums.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.